Jackelyn B. Payne, MPH, MA, on Fertility Preservation in AYAs with Cancer

Video

Payne and colleagues indicated that a significant number of adolescent and young adult women are still not being given the information they desire regarding fertility preservation and therefore are not making fully informed treatment decisions.

According to an article published in the journal ONCOLOGY®,though more adolescent and young adult (AYA) women appear to be engaging in discussions with their oncologists about the risk of fertility loss and fertility preservation options, a significant number are still not being given the information they desire and therefore are not making fully informed treatment decisions.

Given this finding, the researchers suggested that future studies of shared decision-making about fertility preservation should include measures of psychosocial constructs in order to highlight the importance of perceived involvement in decision-making. Additionally, it was indicated that further study of the impact of treatment delays due to fertility preservation is needed in more diverse settings.

“As patients progress to survivorship, regardless of their fertility preservation treatment decision, care teams should continue to monitor fertility outcomes of AYA women and provide them information regarding family planning to protect against further distress, especially as the extent of damage to fertility due to treatment is often uncertain,” the authors wrote.

In an interview with CancerNetwork®, Jackelyn B. Payne, MPH, MA, a doctoral student in the department of Psychology at Stony Brook University and one of the authors of the paper, explained the importance of fertility preservation in this patient population and what more needs to be done to ensure this patient population receives the proper care.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

Payne JB, Flowers CR, Allen PB. Supporting Decision-Making on Fertility Preservation Among Adolescent and Young Adult Women With Cancer. ONCOLOGY.https://www.cancernetwork.com/view/supporting-decision-making-on-fertility-preservation-among-adolescent-and-young-adult-women-with-cancer

Recent Videos
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.